

Safety of Prolonged Intraventricular Administration of Olistin Methanesulphonate

Mairi Ziaka¹, Demosthenes Makris^{1*}, Sophia Markantonis² and Epaminondas Zakynthinos¹

¹*Critical Care Department, University Hospital of Larissa, Larissa, Greece*

²*Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Athens, Greece*

***Corresponding author:** Demosthenes Makris, Department of Critical Care Medicine, University Hospital of Larissa, University of Thessaly School of Medicine, Biopolis, Larisa 41000, Greece, Tel: 302413502960; E-mail: dimomakris@med.uth.gr

Rec date: Mar 09, 2016; **Acc date:** Mar 16, 2016; **Pub date:** Mar 18, 2016

Copyright: © 2016 Ziaka M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Opinion

The recommended duration of intraventricular therapy is between 2 and 56 days [1]. Nevertheless, there have been concerns related to the intraventricular therapy due to the possibility of local or systemic